New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
UP AFTER EARNINGS: Royal Bank of Scotland (RBS), up 9%... Sequenom (SQNM), up 8.2%... Nutrisystem (NTRI), up 11.5%... American Axle (AXL), up 2.9%. ALSO HIGHER: Wynn Resorts (WYNN), up 4% after earnings, shares upgraded at Sterne Agee... Avanir (AVNR), up 3.7% after upgraded at Mizuho... RXi Pharmaceuticals (RXII), up 27.4% after announcing results from study of RXI-109... Intuitive Surgical (ISRG), up 4% after announcing accelerated share repurchase. DOWN AFTER EARNINGS: Chevron (CVX), down 1%... OpenTable (OPEN), down 3.4%... Actuate (BIRT), down 18.2%... SciQuest (SQI), down 20%... ServiceSource (SREV), down 15.2%. ALSO LOWER: Endocyte (ECYT), down 60% after announcing DSMB recommends vintafolide PROCEED trial be stopped. The drug is being developed in partnership with Merck (MRK)... Immunomedics (IMMU), down 16% after filing to sell $30M worth of common stock in a spot secondary offering... InvenSense (INVN), down 9.3% after downgraded at Needham following the company's Q4 earnings report... Blucora (BCOR), down 10% after earnings, downgrade at Craig-Hallum.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
September 29, 2015
10:00 EDTSQNMOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARM Holdings (ARMH) downgraded to Neutral from Buy at Natixis... Arthur J. Gallagher (AJG) downgraded to Hold from Buy at Sandler ONeill... CareDx (CDNA) downgraded to Market Perform from Outperform at Raymond James... Carlisle (CSL) downgraded to Sector Weight from Overweight at KeyBanc... Imation (IMN) downgraded to Hold from Buy at Lake Street... Mediaset Espana (GETVF) downgraded to Underweight from Equal Weight at Barclays... New Source Energy (NSLP) downgraded to Sell from Hold at Wunderlich... Peugeot (PUGOY) downgraded to Buy from Conviction Buy at Goldman... RTL Group (RGXLY) downgraded to Equal Weight from Overweight at Barclays... Regal-Beloit (RBC) downgraded to Neutral from Buy at Buckingham... Sequenom (SQNM) downgraded to Market Perform from Outperform at William Blair... Southern Copper (SCCO) downgraded to Sector Perform at Scotia Howard Weil... TerraForm Global (GLBL) downgraded to Neutral from Overweight at JPMorgan... Verastem (VSTM) downgraded to Hold from Buy at Jefferies... Vital Therapies (VTL) downgraded to Neutral from Buy at SunTrust... Williams (WMB) downgraded to Sector Perform from Outperform at Scotia Howard Weil.
08:38 EDTSQNMSequenom downgraded to Market Perform from Outperform at William Blair
William Blair analyst Brian Weinstein downgraded Sequenom to Market Perform citing near-term headwinds following the company's analyst day. Shares were also downgraded this morning to Sell at Ladenburg.
07:17 EDTRBSRBS CEO eyes share buyback from government, Bloomberg says
Subscribe for More Information
07:04 EDTSQNMSequenom downgraded to Sell from Neutral at Ladenburg
Subscribe for More Information
05:56 EDTSQNMSequenom sees 2020 revenue over $500M
Subscribe for More Information
September 28, 2015
15:18 EDTMRKMerck volatility at 52-week high
Subscribe for More Information
08:02 EDTMRKSyndax and Merck announce patients dosed in trial of Entinostat and Keytruda
Subscribe for More Information
07:52 EDTMRKIIR Holdings to hold a conference
Subscribe for More Information
07:31 EDTMRKMerck says Japan's PMDA approves Marizev DPP-4 inhibitor for Type 2 diabetes
Subscribe for More Information
07:05 EDTRXIIRXi Pharmaceuticals granted patent in China for RXI-109
RXi Pharmaceuticals announced that it has been granted a patent from the State Intellectual Property Office of the People's Republic of China for the composition and methods of use for RXI-109 and other connective tissue growth factor targeting self-delivering RNAi compounds for the treatment of fibrotic disorders, including skin fibrosis. The patent is scheduled to expire in 2031. RXI-109 and other CTGF-targeting sd-rxRNA(R) compounds may be beneficial for the treatment of fibrotic diseases, including dermal scarring, a condition with a much higher prevalence in people with darker skin. Skin pigmentation is classified in VI categories known as the Fitzpatrick scale. In China, individuals tend to have skin types between III and V. The prevalence rates for hypertrophic scarring in individuals with higher-scoring Fitzpatrick phototypes can be up to 40-70% following surgery, making China a significant market for RXI-109 in the treatment of dermal scarring. According to Persistence Market Research, China is predicted to be one of the fastest growing markets for scar treatments in Asia.
06:55 EDTSQNMSequenom to host investor and analyst day
Investor and Analyst Day to be held in New York on September 28 at 2 pm. Webcast Link
September 27, 2015
16:47 EDTMRKMerck reports Phase 1b data on Keytruda for two gastrointestinal cancers
Subscribe for More Information
14:58 EDTMRKMerck announces Phase 1b data on Keytruda for nasopharyngeal cancer
Subscribe for More Information
September 25, 2015
15:31 EDTMRKMerck volatility elevated as shares trend lower
Merck October weekly call option implied volatility is at 39, October is at 34, November is a 29; compared to its 52-week range of 15 to 34, suggesting large price movement after presidential candidate Hilary Clinton announced plans early this week to cap prescription drug prices.
09:11 EDTSQNMSequenom price target lowered to $2.40 from $3 at Piper Jaffray
Subscribe for More Information
09:10 EDTCVXChevron upgraded to Peer Perform from Underperform at Wolfe Research
08:15 EDTMRKMerck narrow Keytruda label may not matter as much as thought, says Bernstein
Subscribe for More Information
07:02 EDTSQNMSequenom sees FY15 revenue $127M-$131M, consensus $141.04M
Subscribe for More Information
September 24, 2015
17:04 EDTMRKMerck, Pfizer to collaborate with Agilent's Dako on Avelumab diagnostic
Subscribe for More Information
16:03 EDTMRKNewLink Genetics awarded $8.1M from DTRA to advance Ebola vaccine
NewLink Genetics (NLNK) announced that the Defense Threat Reduction Agency of the Department of Defense has awarded a subsidiary of NewLink Genetics an $8.1M base contract with future options totaling $5.2M to support various development activities of the investigational rVSV-ZEBOV Ebola) vaccine candidate. NewLink has exclusively licensed research, development and manufacturing of the rVSV-ZEBOV vaccine to Merck (MRK). In late 2014, Merck, known as MSD outside the United States and Canada, licensed the vaccine from NewLink Genetics to apply Merck's vaccine expertise to help accelerate the development of this vaccine candidate. Clinical studies of the rVSV-ZEBOV are ongoing.
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use